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estrone sulfate (E1-S), estrone glucuronide (E1-G), estradiol-3-glucuronide (E2-3G), estradiol-17β-21 
glucuronide (E2-17G), estriol-3-glucuronide (E3-3G), estriol-16α-glucuronide (E3-16G), breast cancer 22 
resistance protein (BCRP, ABCG2), multidrug resistance associated proteins (MRP, ABCC), multidrug 23 
resistance protein 1 (MDR1, P-glycoprotein, P-gp),  UDP-glucuronosyltransferases (UGT), ATP-24 




Estrone, estradiol and estriol are endogenous human estrogens that are rapidly conjugated with 3 
glucuronic acid in both intestinal and hepatic epithelial cells. The resulting glucuronides, estrone-3-4 
glucuronide (E1-G), estradiol-3- and 17-glucuronides (E2-3G and E2-17G), as well as estriol-3- and 16-5 
glucuronides (E3-3G and E3-16G) are found in human plasma and urine. Unlike E2-17G, the efflux 6 
transport of other estrogen glucuronides by human transporters has not yet been investigated 7 
comprehensively. We have studied the transport of E1-G, E2-3G, E3-3G, E3-16G and estrone-3-sulfate 8 
(E1-S), another important estrogen conjugate, using the vesicular transport assay with recombinant 9 
human MRP2, MRP3, MRP4, MDR1 and BCRP that were expressed in insect cells. The transport 10 
screening assays revealed that whereas E1-S was a good and specific substrate for BCRP, the less 11 
transporter-specific conjugates, E1-G and E2-3G, were still transported by BCRP at 10-fold higher rates 12 
than E1-S. BCRP also transported E3-16G at higher rates than the studied MRPs, while it transported E3-13 
3G at lower rates than MRP3. MRP2 exhibited lower or equal transport rates of E1-G, E2-3G, E3-3G and 14 
E3-16G compared to MRP3 and BCRP in the screening assays, mainly due to its high Km values, between 15 
180 and 790 µM. MRP3 transported all the tested glucuronides at rather similar rates, and exhibiting Km 16 
values below 20 µM but lower Vmax values than other transporters. In the case of E3-3G, MRP3 was the 17 
most active transporter in the screening assay. MRP4 transported only E3-16G at considerable rates and 18 
no transport of any tested estrogen conjugates was detected by MDR1. These new results, in combination 19 
with previously reported in vivo human data, stimulates our understanding on the substrate specificity 20 
and role of efflux transporters in disposition of estrogen glucuronides in humans. 21 
 22 
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Keywords: drug transporters, steroid disposition, steroid transport, estrogen, glucuronides, steroid 1 
excretion 2 
1. INTRODUCTION 3 
 4 
Estrogens are important endogenous steroids that play fundamental roles in numerous body functions [1, 5 
2]. In addition, estrogens are widely used as drugs, in both contraception and hormone replacement 6 
therapies. Homeostasis and metabolism of estrogens are complex processes that are regulated by 7 
oxidative and reductive metabolism (phase I), as well as conjugative metabolism (phase II), resulting in 8 
over hundred different biotransformation products in human [3, 4]. The most important naturally 9 
occurring estrogens in women are estriol (E3), estradiol (E2) and estrone (E1). Conjugation of estrogens 10 
with glucuronic acid (i.e. glucuronidation), is catalyzed by several different UDP-11 
glucuronosyltransferase enzymes (UGTs) and results in estrogen glucuronides. These glucuronides are 12 
regarded as end products of estrogen metabolism and they are excreted from the body without further 13 
biotransformation. Glucuronidation of estrogens takes place in various tissues, including the most 14 
prominent metabolizing tissues, namely liver, intestine and kidney [4]. The estrogen metabolizing UGTs, 15 
such as UGT1A1, UGT1A10 and UGT2B7, are expressed at different levels and in a tissue-specific 16 
manner, resulting in variable glucuronidation rates and specificities among different tissues.  17 
Disposition of estrogen glucuronides has a characteristic feature of bile excretion, followed by extensive 18 
enterohepatic circulation, which highlights not only the role of metabolizing enzymes but also the role 19 
of active efflux transport of the conjugated estrogens in the liver [5, 6]. However, despite extensive bile 20 
excretion and enterohepatic circulation of estrogen conjugates, high amounts of conjugated estrogens are 21 
also found in the human blood circulation and are excreted, eventually, via urine [7, 8]. Estrone-3-22 
glucuronide (E1-G), estradiol-3- and estradiol-17-glucuronide (E2-3G and E2-17G), estriol-3 and estriol-23 
16-glucuronide (E3-3G and E3-16G) are the glucuronosyl conjugates of estrone, estradiol and estriol, 1 
respectively (Fig. 1). Estrone sulfate (E1-S) is the most abundant estrogen conjugate in the blood 2 
circulation and, possibly, acting as a reservoir for free estrogens [3, 4, 7].  The concentration of E1-S 3 
varies in healthy individuals between 0.5-5 nM, but up to 180 nM has been measured during pregnancy 4 
[7, 8, 9]. The plasma concentration of estrogen glucuronides is generally over ten-fold lower, with 5 
increased concentrations during pregnancy, similarly as for E1-S. 6 
(Figure 1) 7 
Human ATP-binding cassette (ABC) transporters are a family of multiple efflux transporters that utilize 8 
ATP to actively transport compounds across biological membranes [10, 11]. ABC transporters include 9 
several pharmacologically, but especially pharmacokinetically, relevant transporters that are localized on 10 
plasma membranes of polarized cells [11]. Among them are the multidrug resistance associated proteins 11 
2, 3 and 4 (MRP2-4, ABCC2-4) and the breast cancer resistance protein (BCRP, ABCG2), which are 12 
localized on either the apical or basolateral membranes of human enterocytes, hepatocytes and proximal 13 
tubular cells [12, 13]. They contribute to systemic exposure and biliary, intestinal and urinary excretion 14 
of their substrates that mostly are anionic and include glucuronide conjugates of drugs, other xenobiotics, 15 
as well as endogenous compounds [14]. MRP2 and BCRP are expressed on apical membranes in both 16 
hepatocytes and enterocytes, where they restrict systemic exposure of their substrates [12, 13]. MRP3 is 17 
localized on the opposite membranes, basolateral, in the same polarized cells, contributing to systemic 18 
exposure of its substrates. MRP4 is also expressed on basolateral membranes of hepatocytes and 19 
enterocytes, but it might have a more prominent role in the kidneys, where it is expressed on luminal 20 
membranes of the proximal tubular cells, by contributing to active secretion of its substrates into urine 21 
[12, 13, 15, 16]. 22 
Not much is currently known about the interactions of E1-G, E2-3G, E3-3G and E3-16G with the human 1 
transporters MRP2, MRP3, MRP4 and BCRP. Contrary to the above, the transport of E2-17G has been 2 
well characterized and it is a prominent substrate for all of the above transporters, as well as for several 3 
uptake and other efflux transporters [14, 17]. In addition, the transport of E2-17G by multidrug resistance 4 
protein 1 (MDR1, P-glycoprotein, P-gp) is reported, although this transporter is not generally considered 5 
to be involved in the transport of phase II conjugates [14, 18]. On the other hand, E1-S is a very good and 6 
widely used substrate for BCRP, as well as for several uptake transporters [14, 17]. Of the four estrogen 7 
glucuronides included in this study, E2-3G was previously reported to be a rather good substrate for 8 
MRP2, but to lack the distinctive cooperative transport kinetics which is typical for the transport of E2-9 
17G by MRP2 [19].  10 
We have now studied the efflux transport of physiologically important estrogen conjugates E1-G, E1-S 11 
E2-3G, E3-3G and E3-16G (Fig. 1) by recombinant human transporters MRP2, MRP3, MRP4, MDR1 12 
and BCRP, using the membrane vesicle transport assay. Our aims were to explore the substrate specificity 13 
and kinetic differences between these transporters, in vitro, in order to improve the understanding of 14 
estrogen conjugate disposition in vivo. The results add to the scarce knowledge of steroid conjugates 15 
transport by human efflux transporters, an important topic in cancer and drug research. 16 
 17 
  18 
2. MATERIALS and METHODS 1 
2.1 Chemicals and solvents 2 
Sodium salts of E2-17G, E3-3G and E1-S, as well as E3-16G were from Sigma Aldrich (St. Louis, MO, 3 
USA), sodium salt of E1-G was from Toronto Research Chemicals (Toronto, ON, Canada) and sodium 4 
salt of E2-3G from Cayman Chemical (Ann Arbor, MI, USA). Tritium-labelled E1-S (6, 7-
3H, as 5 
ammonium salt, specific activity 54 mCi/µmol) and the liquid scintillation cocktail (Optiphase Hisafe 3) 6 
were from Perkin Elmer (Waltham, MA, USA). All solvents and formic acid were of analytical grade or 7 
better and were obtained from Sigma-Aldrich. Water for the analyses and assays was purified using Milli-8 
Q water purification system and filtered through 0.22 µM filter (Merck Millipore, Darmstadt, Germany).  9 
2.2 Expression and vesicle preparation of human MRP2, MRP3, MRP4, MDR1 and BCRP  10 
The human recombinant transporters MRP2, MRP3, MRP4, MDR1 and BCRP were expressed in 11 
baculovirus-infected Sf9 insect cells and inside-out membrane vesicles were prepared from them and 12 
used for the vesicular transport assays (see section 2.3) as previously described [20-24]. In addition, 13 
control vesicles (CtrlM for MRP2-MRP4 and Ctrl+C for MDR1 and BCRP, see below) were prepared 14 
from Sf9 insect cells that were transfected with baculovirus containing no human cDNA. 15 
MDR1 and BCRP vesicles were supplemented with additional cholesterol to enhance their transport 16 
activity, as reported previously [25, 26] and carried out in our laboratory [21-24]. Accordingly, 17 
cholesterol loaded control vesicles (Ctrl+C) were used as controls in MDR1 and BCRP assays. 18 
2.3 Vesicular transport assays 19 
The vesicular transport assays were carried out in 96-well polystyrene plates at a final volume of 75 µl 20 
per well, as previously described [19, 20, 21, 22]. The assay mixture consisted of 40 mM MOPS (adjusted 21 
to pH 7.0 with Tris-HCl), 6 mM MgCl2, 60 mM KCl, 7 mM Tris-HCl, 7 mM mannitol and 0.3 mM 22 
EGTA. The total vesicle protein amount in the assays were either 40 µg (MRP2, MRP3, MRP4, MDR1 1 
and CtrlM) or 20 µg (BCRP and Ctrl+C) per well. The substrate stock solutions were prepared in DMSO, 2 
at 50 mM concentration, and stored at -20 °C. Subsequent substrate dilutions were done in the assay 3 
buffer (MOPS-MgCl2-KCl), resulting in a final DMSO concentration of either 0.02% (initial screening 4 
assays) or 1.0% (kinetic assays) in the transport assay. 5 
Transport assay mixtures were prepared on ice prior the pre-incubation at 37 °C for 10 min. Transport 6 
reactions were initiated by the addition of either Mg-ATP to a final concentration of 4 mM (+ATP 7 
samples) or blank reaction mixture (-ATP samples), both pre-incubated at 37 °C. The transport assays, 8 
following initiation, were carried out for pre-determined times (1-6 min, see figure legends for the 9 
incubation time of each experiment) at 37 °C and constant shaking at 500 rpm. For kinetic assays, the 10 
incubation times were selected based on the linear transport of each substrate-transporter combination 11 
(See data in the supplementary material, Fig. S1). The transport reactions were quenched by adding 200 12 
µl of cold buffer (70 mM KCl and 40 mM MOPS pH 7.0) and were transferred to a 96-well filter plate 13 
(pore size 1.0 µm, glass fiber filters, from Merck Millipore, Darmstadt, Germany). The samples were 14 
then filtered and washed with five aliquots of the same cold buffer under vacuum filtration. The filter 15 
plate was subsequently dried at room temperature, after which 100 µl of 1:1 acetonitrile: 0.2% formic 16 
acid in water, containing E2-17G as internal standard, was applied to each well. The plate was then 17 
incubated at room temperature for 30-60 min under gentle shaking. Finally, the filter plate was 18 
centrifuged for 2 min at 3000 g to collect the samples (filtrate) into a new well plate and the samples 19 
were subjected to analysis by LC-MS/MS (see section 2.4).  20 
Unlike the estrogen glucuronides, the transport of E1-S was assayed using a radioactively labelled 21 
compound. In this case, the transport assays included 1-150 nCi of tritium labelled E1-S per well. The 22 
transport reactions were carried out as described above for the estrogen glucuronides, but quantification 23 
of E1-S was done by the addition of 50 µl scintillation cocktail to each well, followed by incubation of 1 
the plate at room temperature for 30 min before radioactivity counting using a Microbeta 1450 Trilux 2 
scintillation counter (from Wallac, Turku, Finland). In addition, when labelled E1-S was used the filter-3 
plate was pre-soaked, before transferring the assay samples, with 100 µl of 50 µM unlabeled E1-S to 4 
decrease the unspecific binding of labelled compound. 5 
Transport assays were conducted in triplicate samples for each time and concentration point, including 6 
both +ATP and –ATP samples. The experimental data are reported as means ± SD of retained compound 7 
within the vesicles per amount of total vesicle protein per incubation time, resulting in pmol/min/mg total 8 
protein values. Kinetic assays were conducted using at least six different substrate concentrations and 9 
the data are reported as means of ATP-dependent transport ± SD after subtracting the -ATP values from 10 
the +ATP values. Kinetic data were fitted to the Michaelis-Menten equation (v = Vmax [S] / ([S] + Km)), 11 
using least squares fit in GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA), that was 12 
used also for data visualization. The goodness of fit was inspected in each case visually, using the Eadie-13 
Hofstee transformation of the experimental data (Suppl. Fig. 2), as well as the coefficient of 14 
determination (R2) value of the fit (Table 1). In addition, linear substrate transport versus concentration, 15 
in the absence of ATP (passive), was inspected to exclude artifacts, such as solubility limitations, during 16 
the assays. The substrate solubility in the reaction mixtures, at the used concentrations, was tested before 17 
the transport assays by HPLC analyses, visual inspection and nephelometer analyses (Nepheloskan 18 
Ascent, Labsystems, Finland). 19 
2.4 Analytical methods 20 
The amounts of E1-G, E2-3G, E3-3G and E3-16G that was retained in the vesicles at the end of the 21 
transport assays, were quantified by triple quadrupole mass spectrometry (Xevo TQ-S), connected to an 22 
Ultra Performance Liquid Chromatography (ACQUITY UPLC I Class), both from Waters (Milford, MA, 23 
USA). Samples on a 96-well plate (kept at 15 °C) were injected (1-5 µl) into Acquity UPLC BEH C18 1 
(2.1x100 mm, 1.7 µm from Waters) column that was kept at 30 °C and operated at a flow rate of 0.4 2 
ml/min. The chromatography eluents were water (A) and acetonitrile (B), both containing 0.1% formic 3 
acid. The gradient program (0-2.5 min 10% B to 65% B, 2.5-4 min 95% B followed by at least 1 min 4 
equilibrium at 10% B) was used to elute E3-3G, E3-16G, E2-3G, E2-17G (internal standard) and E1-G at 5 
1.33, 1.72, 1.95, 2.08 and 2.16 min, respectively.  6 
The mass spectrometry was operated in negative electrospray ionization mode, using nitrogen as ion 7 
source gas and argon as collision gas, both from Aga (Espoo, Finland). The operation parameters were 8 
set as following: capillary voltage at -2.0 kV, cone at 1.0 V, source offset at 50 V, source temperature at 9 
150 °C, cone gas flow at 150 l/h, nebulizer gas pressure at 7.0 bar, as well as desolvation gas temperature 10 
and flow rate at 650 °C and 1100 l/h, respectively. Quantification was done using MS/MS mode, by 11 
selecting deprotonated precursor ions [M-H]- at the first quadrupole (463.2 m/z for E3-3G and E3-16G, 12 
447.2 m/z for E2-3G and E2-17G and 445.2 m/z for E1-G), fragmenting them at the second quadrupole 13 
(collision energies were 45 V, 30 V, 35 V, 28 V and 38 V for E3-3G, E3-16G, E2-3G, E2-17G and E1-G, 14 
respectively) and monitoring the product ions resulting from the loss of glucuronic acid [M-H-176]- 15 
(287.2 m/z for E3-3G and E3-16G, 271.2 m/z for E2-3G and E2-17G, as well as 269.2 m/z for E1-G). An 16 
additional product ion at 113.0 m/z, for qualitative confirmation, was monitored for all the analytes using 17 
20-30 V collision energies. Dwell time was 100 ms for all the monitored reactions. 18 
The ratio of analyte to internal standard (E2-17G) was used for the quantification. The standard curve 19 
samples were prepared similarly to the test samples, namely in 100 µl of 1:1 acetonitrile: 0.2% formic 20 
acid in a water containing E2-17G as internal standard and filtered through pre-wetted and dried filter 21 
well plates. The linear range of quantification (R2 ≥ 0.99 in each case) was adjusted for each assay and 22 
compound, usually the lower limit for quantification was 1 nM and the upper limit of quantification was 1 
1000-5000 nM, depending on the analyte.  2 
3. RESULTS 1 
3.1 Screening of estrogen conjugate transport 2 
The transport of estrogen glucuronides and E1-S (see structures in Fig. 1) was first tested using a single 3 
substrate concentration of 10 µM (for time-dependent transport, also when no transport activity was 4 
found, of the all tested estrogen conjugates and transporters, see Supplementary figure S1). The results 5 
of the initial screening experiment clearly showed that E1-S was not transported by any of the tested 6 
MRPs (Fig. 2A). Even the addition of 5 mM glutathione (GSH) to the transport assays did not change 7 
this (results not shown). In sharp contrast to the MRPs, BCRP transported E1-S at high rates (Fig. 2A), 8 
in agreement with previous reports [14, 27]. 9 
BCRP was also highly active in the transport of E1-G (Fig. 2B) and E2-3G (Fig. 2C). In the case of estriol 10 
glucuronides, however, BCRP exhibited much lower activity toward E3-3G in comparison to E1-G and 11 
E2-3G (Fig. 2D). On the other hand, BCRP transported E3-16G at higher rates than each of the studied 12 
MRPs, but the rate was still clearly lower than in the case of E1-S, E1-G and E2-3G (Fig. 2E).  13 
(Figure 2) 14 
The transport activity of MRP2 in the initial screening toward E1-G and E3-G was lower in comparison 15 
to E2-3G and E3-16G (Fig. 2B-E). However, even in both latter cases the activity of MRP2 was clearly 16 
lower than the activity of BCRP and similar to the rates exhibited by MRP3 (Figs. 2B and 2C). 17 
MRP3 transported all of the tested estrogen glucuronides at rather similar rates, at least under the 18 
conditions of the initial screening experiments where the substrate concentration was 10 M (Figs. 2B-19 
2E). MRP4, on the other hand, transported only E3-16G at considerable rates (Fig. 2B-E), exhibiting 20 
quite clear and narrow selectivity in the transport of the studied estrogen glucuronides. Of the transporters 21 
included in this study, MDR1 was the only one not transporting any of the tested estrogen conjugates 1 
(Fig. 2 and Supplementary figure S1).  2 
It should be noted here that rate comparisons between different efflux transporters in this study, 3 
particularly when the differences are not very large, should be considered with care. Presently, we do not 4 
have a method to accurately measure the amount of active transporter in the vesicle preparations. On the 5 
other hand, the transport rates of different substrates by the same transporter could be compared reliably 6 
in this study, since they were done with the same vesicle preparation.  7 
3.2 Kinetic analysis of estrogen conjugate transport 8 
Kinetic analyses were carried out for all the tested transporters that exhibited substantial activity in the 9 
initial screening assay (Fig. 2). The kinetic curves are presented for each transporter separately (Figs. 3-10 
5) and the derived kinetic constants of the fitted model are listed in Table 1.  11 
The kinetic assay results of BCRP transport of E1-G and E2-3G (Fig. 3A) revealed that this transporter 12 
reaches higher Vmax values with these glucuronides than any other studied transporter, while its Km values 13 
are in the moderate range, below 100 µM (Table 1). In the case of E1-S, the Km value for BCRP was very 14 
low, 1.2 µM (Fig. 3B and Table 1). However, the Vmax of E1-S transport by BCRP was around 10-fold 15 
lower than for E1-G and E2-3G, whereas the Km values for these estrogen glucuronides, although in the 16 
moderate range, were over 60-fold larger than for E1-S transport by BCRP (Table 1). The transport 17 
kinetics of E3-3G by BCRP was not saturable at the studied concentrations (Fig. 3C), a result that is in 18 
agreement with the initial screening result that revealed lower transport rates of this glucuronide by 19 
BCRP (Fig. 2D). Contrary to E3-3G, the transport of E3-16G by BCRP was saturable at low 20 
concentrations, yielding a low Km value of 29 µM (Fig. 3C and Table 1), but also a Vmax value in the 21 
same range as for the transport of E1-S, namely much lower than the Vmax values of BCRP transport for 1 
E3-3G or E1-G and E2-3G (Table 1). 2 
(Figure 3) 3 
MRP2 exhibited lower active transport rates of E1-G, E2-3G, E3-3G and E3-16G in the initial screening 4 
assays (Figs. 2B-E) and the kinetic analyses (Fig. 4) suggest that the prime reason for this was higher Km 5 
values in comparison to other transporters, particularly in the cases of estriol glucuronides, not lower 6 
Vmax values (Table 1). The transport kinetics of the studied estrogen glucuronides by MRP2 followed the 7 
Michaelis-Menten equation (Fig. 4, Table 1 and Suppl. Fig 2) and no indication of cooperative kinetics 8 
for MRP2 was found, when the data was analyzed by Eadie-Hofstee transformations (Suppl. Fig. 2). 9 
MRP2 follows such a cooperative kinetics in the transport of E2-17G, another estrogen glucuronide [14]. 10 
(Figure 4) 11 
The transport of estrogen glucuronides by MRP3 differed from the other tested transporters by its nearly 12 
similar rates for all the tested glucuronides in the initial screening assays (Fig. 2B-E). The kinetic analyses 13 
(Figs. 5A and 5B) further revealed that in the case of MRP3, there were no large differences between the 14 
transport kinetics of the studied estrogen glucuronides. The maximal transport velocities varied by no 15 
more than two-fold and the Km values ranged from 2.8 to 18.2 µM (Table 1), demonstrating similar 16 
transport activity for E1-G, E2-3G, E3-3G and E3-16G by MRP3. These results also indicate that the 17 
affinity of MRP3 for the transport of all the tested estrogen glucuronides is higher than the corresponding 18 
values for BCRP and MRP2, even if the Vmax values of MRP3 are generally lower. 19 
(Figure 5) 20 
Among the tested transporters, only MRP4 exhibited selective transport of only one of the studied 21 
compounds, E3-16G, at substantial rates (Fig. 2). Kinetic analysis revealed that this transport follows the 22 
Michaelis-Menten equation and both the Km and the Vmax values of MRP4 are higher than the 1 
corresponding values for E3-16G transport by MRP3 (Fig. 5C and Table 1). 2 
  3 
4. DISCUSSION 1 
The most frequently used substrate for efflux transporters, E2-17G, is an estrogen glucuronide [14]. In 2 
this study, however, we have examined the transport of four other estrogen glucuronides and an estrogen 3 
sulfate, by the ATP-dependent efflux transporters MRP2, MRP3, MRP4, MDR1 and BCRP. Our results 4 
reveal new information on the substrate specificity of the transporters and differences between them in 5 
this respect. It is essential to consider these results taking into account the location of each transporter in 6 
polarized epithelial cells of human intestine, liver and kidney (Fig. 6), since this could determine and 7 
affect the disposition of the studied estrogen conjugates in vivo. 8 
While we cannot directly compare the transport rates and Vmax values by the recombinant transporters to 9 
each other, since expression levels may differ somewhat among vesicle preparations, the changes in these 10 
values from one substrate to another and the magnitude of the values are clearly informative. In addition, 11 
the kinetic analyses provide indications on respective affinity to the substrates and how it differs among 12 
transporters and between substrates.  13 
(Figure 6) 14 
4.1. Transport of E1-S 15 
No transport of E1-S was observed by any other transporters studied here except BCRP that transported 16 
E1-S at a high affinity, as suggested by the low Km value (Figs. 2A and 3B, and Table 1). The E1-S 17 
transport results are in line with previously published findings for BCRP, MRP2 and MRP3 [27-29]. 18 
Like MRP2 and MRP3, the additional efflux transporter included in this study, MRP4, also did not 19 
exhibit transport activity toward E1-S (Fig. 2A). It may be interesting to note that similar results were 20 
previously found for the sulfate metabolite of the synthetic estradiol derivative, ethinylestradiol sulfate 21 
that was transported by BCRP, but not by MRP2, MRP3 or MRP4 [30, 31]. 22 
Since E1-S is found at high amounts in the bile [32], apical excretion in the liver could be explained by 1 
BCRP that solely transported this compound (Figs. 2A and 3B, and Table 1). Nonetheless, E1-S is also 2 
found in the human blood circulation, suggesting that a basolateral transport from the liver takes place, 3 
in addition to the apical transport into bile [4, 7]. Hence, an interesting question is how E1-S crosses the 4 
basolateral membranes of the liver. MRP4 could have been a candidate transporter for this transport since 5 
it carries steroid sulfates such as dehydroepiandrosterone sulfate [14]. However, under our experimental 6 
conditions no E1-S transport by MRP4, neither by the other basolateral transporter MRP3, was observed 7 
(Fig. 2A). Thus, it is likely that other basolateral transporters are involved in the systemic excretion of 8 
E1-S in human. It has actually been reported that MRP1 and OSTα/β transport E1-S in vitro and this might 9 
explain the hepatic in vivo basolateral transport of E1-S, although the former transporter may be 10 
expressed at low levels in healthy human livers [33-36]. Further studies are needed to fully clarify this 11 
issue. 12 
4.2. Transport and disposition of E1-G and E2-3G 13 
In the human intestine, estrone undergoes direct glucuronidation and sulfation, whereas in the liver only 14 
estrone sulfation is catalyzed at high rates [37, 38]. Estrone glucuronidation is catalyzed almost only by 15 
the extrahepatic UGT1A10 [38], while its sulfonation is primarily catalyzed by the high-affinity 16 
sulfotransferase SULT1E1 that is expressed in both the liver and small intestine [37]. Obviously, the 17 
expression level of UGTs and SULTs in different tissues have an effect on the over 10-fold higher 18 
concentrations of E1-S than E1-3G in human plasma [7, 39]. However, intestinal and hepatic efflux 19 
transporters, including their localization in the plasma membranes may also contribute to relative plasma 20 
levels of estrone glucuronide and sulfate. Unlike estrone, estradiol is mainly glucuronidated in the liver 21 
resulting in E2-17G as the main glucuronide and E2-3G as a minor product [40, 41]. In the intestine, 22 
however, estradiol is almost exclusively glucuronidated to E2-3G [40].  23 
The rapid metabolism of exogenously administered estradiol to estrone, and partly to estriol, complicates 1 
the determination of glucuronidation contribution to total estradiol metabolism and the subsequent 2 
impact of different efflux transporters on the disposition of estradiol glucuronides [1, 39]. In addition, 3 
particularly in the case of E2-17G, the hepatic uptake transporters may also play important roles in its 4 
disposition, as indicated by the facts that there is only minor direct urinary excretion of E2-17G when it 5 
was administered, as such, via parenteral route, which is in line with findings using in vitro expressed 6 
hepatic uptake transporters [17, 42]. E2-17G is known to be a substrate for all of the efflux transporters 7 
included in this study [14], while the other glucuronide of estradiol, E2-3G, was transported by the same 8 
transporters as E2-17G except MRP4 in this study (Fig 2C). 9 
Interestingly, none of the transporters appear to differ between transport of E1-G and E2-3G. However, 10 
the affinity of MRP3 toward E1-G and E2-3G, as suggested by its Km values for these glucuronides, is 11 
10-fold higher than in the case of BCRP, while Km values of MRP2 for both glucuronides were rather 12 
high, suggesting poor affinity (Figs. 3A, 4A, 5A and Table 1). Contrary to E2-17G, in the cases of E1-3G 13 
and E2-3G the hepatic uptake transporters might play less prominent roles and these glucuronides have 14 
been reported to be excreted mainly into urine from the blood circulation, without further enterohepatic 15 
circulation [42, 43]. Thus, systemic excretion of E1-G and E2-3G may be controlled by MRP3 in the 16 
basolateral membranes of intestine. Nevertheless, also apically expressed MRP2 and BCRP could 17 
contribute to the disposition of E1-G and E2-3G (Figs. 2-6 and Table 1), especially in the intestine where 18 
these glucuronides are formed and both the above transporters are expressed [12, 38, 40]. It should be 19 
noted that UGT1A10 and MRP3 have higher and BCRP lower expression in the larger intestine than in 20 
the small intestine, which may mean that more E1-3G and E2-3G are formed in the distal intestine from 21 
unconjugated estrogens and subsequently these glucuronides are transported to the blood circulation by 22 
MRP3 [44, 45].  23 
(Table 1) 1 
4.3. Transport and disposition of E3-3G and E3-16G  2 
Estriol is considered to be an end product of estrogen metabolism (endogenous and exogenously 3 
administered) and it is extensively conjugated directly to E3-3G and E3-16G in the intestine, or only to 4 
E3-16G in the liver [1, 5, 46]. After oral administration of estriol, the glucuronides circulate at relatively 5 
high levels, almost 1000-fold higher than the parent compound, until they are finally excreted into urine 6 
[1, 47, 48]. The enterohepatic circulation of estriol conjugates does not seem to be as extensive as for 7 
estradiol and estrone conjugates [5, 6, 49]. In the urine, E3-16G is the major metabolite of estriol and the 8 
intestinal specific metabolite E3-3G is present at about 10-20% of the total estriol [50, 51]. 9 
The observations above suggest that efflux transporters are responsible for most of the estriol glucuronide 10 
disposition. The predominant role of the basolateral efflux of estriol glucuronides is in line with our 11 
results (Figs. 2D and 2E and Table 1). We found that of the tested transporters, E3-3G has a high affinity 12 
only to MRP3 (Fig. 5B and Table 1). This result supports the significance of basolateral excretion of this 13 
glucuronide from the human intestine. Based on our results, E3-3G seems to be a rather specific substrate 14 
for MRP3 in the human small intestine. This may mean that oral administration of estriol, followed by 15 
plasma profiles of E3-3G, could serve as a marker for intestinal MRP3 function. Especially, because there 16 
is no indication of active uptake of E3-3G into the liver or other tissues and this glucuronide is rapidly 17 
excreted into urine when it is administered to humans, as such [52]. In addition, larger intestine could be 18 
exposed to higher amounts of unconjugated estriol, which could result in high amounts of E3-3G, because 19 
of the enzymes catalyzing estriol glucuronidation, only UGT1A10 is expressed in this tissue [45, 46]. 20 
Significance of MRP3 in the disposition of E3-3G may be also high in the larger intestine, because its 21 
higher expression compared to the small intestine [44]. 22 
Although estriol carries two hydroxyl groups in the D ring, hepatic glucuronidation occurs only at the 1 
hydroxyl in the 16, not 17 position, resulting in the formation of E3-16G [46]. We found a high affinity 2 
transport of E3-16G by the basolateral transporter MRP3, whereas the affinity for E3-16G by the other 3 
rather highly expressed hepatic transporter, the apical MRP2, as far as suggested by the Km value, was 4 
low (Figs. 4B and 5B, Table 1). In addition, BCRP and MRP4 transported E3-16G with moderate Km 5 
values (Figs. 2C and 2B, Table 1). Thus, it is likely that MRP3 is the main contributor to the disposition 6 
of E3-16G from the liver, due to its lower Km value and higher expression level in comparison to MRP4 7 
and BCRP [36]. Our results and the latter suggestion are supported by reported findings in humans that 8 
have indicated the predominant excretion route of E3-16G to be into circulation and then subsequently to 9 
the urine, even if some E3-16G is also excreted into bile [5, 6, 49-51]. However, how much each 10 
transporter contributes to the disposition of E3-16G in the liver, is difficult to determine or predict, not 11 
least due to variability in expression levels of the different transporters in this tissue [36]. Especially 12 
MRP4 and BCRP are reported to be expressed at low levels in healthy human livers in comparison to 13 
MRP2 and MRP3 [35, 36]. In addition, hepatic uptake transporters might also contribute to disposition 14 
of E3-16G, as indicated by some biliary excretion following its administration, as such, to humans via 15 
parenteral route [49, 53]. 16 
In humans, active kidney secretion of E3-16G has been reported [47, 48]. Our in vitro results are in 17 
agreement with this, since E3-16G was transported by both MRP2 and MRP4, two important kidney 18 
transporters [12, 13] (Fig. 2E and Table 1). The renal clearance of E3-16G exceeds inulin clearance by 19 
3-8 times, whereas the renal clearance of E3-3G (not transported by MRP4, Fig. 2D) is only 1-2 times 20 
that of inulin clearance, when both conjugates are formed from endogenous estriol [47, 48]. However, 21 
estriol may also be glucuronidated, in vivo, in the human kidney to E3-16G, but not to E3-3G, a factor 22 
that complicates comparison between the renal clearances of these two glucuronides [54]. On the other 23 
hand, the ratio between estriol glucuronides and the parent compound in the blood circulation is 1 
remarkably high, almost 1000, suggesting that the renal glucuronidation may only have a small impact, 2 
and the high excretion of E3-16G is a result of uptake from the circulation and subsequent efflux transport 3 
in the kidney [1]. While MRP2 is also expressed on the apical membranes of proximal tubule cells [12], 4 
the results of this study showed that the Km value of MRP2 for the transport of E3-16G is more than 10-5 
fold higher than the corresponding value of MRP4 (Table 1), suggesting that MRP4 is likely to be play 6 
a major role in the renal excretion of E3-16G. 7 
It may be interesting that while each of the tested transporters exhibited rather similar activity and kinetics 8 
toward both E1-3G and E2-3G (Figs. 3-5), two of the estrogens that carry glucuronic acid in the ring A, 9 
this similarity does not extend to E3-3G, even though its glucuronic acid is in the exact same position as 10 
in E1-3G and E2-3G (Fig. 1). The difference between transport of E1-3G, E2-3G and E3-3G is most 11 
obvious in the case of BCRP (Figs. 2D and 3C, and Table 1), but is also seen in MRP2. MRP3, in contrast 12 
to BCRP and MRP2, was only little affected by the substrate change to E3-3G, even if its Km value in 13 
this case was somewhat higher than for any other of the glucuronides in this study, including E3-16G 14 
(Table 1). While it is currently unclear why the differences between estradiol and estriol have strong 15 
effect on BCRP and MRP2, this might provide a tool to explore the structure of the binding sites of these 16 
transporters and understand similarities and differences between them. 17 
Summary 18 
We have studied here the efflux transport of E1-G, E2-3G, E3-3G, E3-16G and E1-S by recombinant 19 
human transporters MRP2, MRP3, MRP4 and BCRP, using inside-out membrane vesicles. We found the 20 
highest transport activity of BCRP toward E1-G and E2-3G and lower to E1-S. While E1-S was a specific 21 
substrate for BCRP, E1-G and E2-3G were transported by BCRP at much higher rates, but at lower 22 
apparent affinity than E1-S. MRP2 exhibited low affinity and MRP3 rather high transport affinity to all 23 
the tested estrogen glucuronides, but at moderate rates. As a result, E3-3G was efficiently transported 1 
almost only by MRP3. From the tested estrogen glucuronides, MRP4 transported only E3-16G. Our 2 
results provide new details and in vitro explanations for most of the already known in vivo disposition 3 
data of estrogens, thereby improving our understanding of how these estrogen glucuronides are disposed 4 
in humans and what are the underlying molecular mechanisms. 5 
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The kinetic parameters are derived from the experimental data, presented in Figures 3-5, fitted in the 15 
Michaelis-Menten equation. The 95% confidence intervals (CI) for the derived kinetic values are 16 





µM (95% CI) 
Vmax 
pmol/mg/min (95% CI) 
R2 
MRP2 
E1-G 241 (210-273) 884 (830-938) 0.99 
E2-3G 180 (145-216) 1700 (1560-1840) 0.97 
E3-3G 791 (640-942) 1800 (1560-2030) 0.99 
E3-16G 773 (596-949) 6440 (5330-7540) 0.99 
MRP3 
E1-G 7.3 (5.6-8.9) 182 (171-194) 0.92 
E2-3G 2.8 (2.0-3.6) 260 (245-274) 0.86 
E3-3G 18 (16-21) 441 (419-463) 0.98 
E3-16G 4.8 (3.4-6.3) 195 (180-211) 0.90 
MRP4 
E3-16G 65 (53-77) 522 (491-554) 0.96 
BCRP 
E1-G 74 (65-82) 9310 (8940-9690) 0.99 
E2-3G 81 (50-112) 7910 (7010-8810) 0.88 
E3-3G 1020 (736-1300) 4410 (3500-5320) 0.99 
E3-16G 29 (21-37) 1080 (1000-1170) 0.92 
E1-S 1.2 (0.78-1.7) 817 (745-889) 0.83 
FIGURE LEGENDS 1 
Fig. 1. Structures of the estrogen conjugates. 2 
Structures of the studied glucuronides of estrone, estradiol and estriol, estrone sulfate and E2-17G. 3 
Fig. 2. Screening results of E1-S, E1-G, E2-3G, E3-3G and E3-16G transport.  4 
Transport of E1-S (A), E1-G (B), E2-3G (C), E3-3G (D) and E3-16G (E) by MRP2, MRP3, MRP4, MDR1 5 
and BCRP was studied using 10 µM substrate concentration and 2 min incubation. The transport assays 6 
were conducted in the presence (colored bars) or absence (open bars) of ATP, and contained 40 µg 7 
(MRPs, MDR1 and CtrlM) or 20 µg (BCRP and Ctrl+C) of total vesicle protein per sample. Control 8 
vesicles, containing no human transporter, were included in all assays and are presented as CtrlM for 9 
MRPs, or Ctrl+C for MDR1 and BCRP (MDR1, BCRP and Ctrl+C vesicles were supplemented with 10 
cholesterol, see section 2.2). The presented results are from a single experiment that was conducted in 11 
triplicate samples, and the error bars represent ±SD. 12 
Fig. 3. BCRP transport kinetics of E1-S, E1-G, E2-3G, E3-3G and E3-16G. 13 
The ATP-dependent BCRP transport kinetics of E1-G and E2-3G (A), E1-S (B) and E3-3G and E3-16G 14 
(C) were studied during 1 min (E1-S), 2 min (E1-G, E2-3G and E3-16G) or 6 min (E3-3G) incubations. In 15 
each sample, the total vesicle protein amount was 20 µg. The fitted model was the Michaelis-Menten 16 
equation and the fitting is presented by the lines. The data points represent means of the ATP-dependent 17 
values ± SD, from a single experiment conducted in triplicate samples.  18 
Fig. 4. MRP2 transport kinetics of E1-G, E2-3G, E3-3G and E3-16G. 19 
The ATP-dependent MRP2 transport kinetics of E1-G and E2-3G (A), as well as E3-3G and E3-16G (B), 20 
were assayed either for 2 min (E2-3G and E3-16G) or 6 min (E1-G and E3-3G). In each sample, the total 21 
vesicle protein amount was 40 µg. The fitted model was the Michaelis-Menten equation and the fitting 1 
is presented by the lines. The data points represent means of the ATP-dependent values ± SD from a 2 
single experiment conducted in triplicate samples. 3 
Fig. 5. MRP3 transport kinetics of E1-G, E2-3G, E3-3G and E3-16G, and MRP4 transport kinetics 4 
of E3-16G. 5 
The ATP-dependent MRP3 transport kinetics of E1-G and E2-3G (A), as well as E3-3G and E3-16G (B), 6 
were assayed for either 1 min (E2-3G) or 2 min (E1-G, E3-3G and E3-16G). The ATP-dependent MRP4 7 
transport kinetics of E3-16G (C) was studied using 2 min incubation. In each sample, the total vesicle 8 
protein amount was 40 µg. The fitted model was the Michaelis-Menten equation and the fitting is 9 
presented by the lines. The data points represent means of the ATP-dependent values ± SD from a single 10 
experiment conducted in triplicate samples. 11 
Fig. 6. Disposition human estrogen conjugates; a schematic presentation based on a combination 12 
of new and previous results.  13 
Transporters are represented as white arrows, the width of which indicates whether it is relatively highly 14 
or lowly expressed in the tissue and dashed outlines stand for speculative transporters or mechanisms 15 
that have limited evidence. The liver image stands for a typical hepatocyte. Conjugated and 16 
unconjugated estrogens are represented by abbreviations containing numbers and letters. The compounds 17 
abbreviation denotes the type of estrogen (E1, E2, and E3 standing for estrone, estradiol, and estriol) and 18 
the latter part describes the conjugation position and the type of conjugate, as in the text. Larger 19 
compound names indicate higher transport rates of the given substrate by the specific transporter. Black 20 
arrows inside the cells represent estrogen biotransformation reactions and the relative extent of these 21 
reactions. 22 
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Figure S1: Eadie-Hofstee transformations of the data presented in Figures 3-5 3 
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Fig S2. Eadie-Hofstee transformations of the data presented in Figures 3-5. For further details see 
the Figures 3-5 in the main text.
